In this episode of Redcliffe Cardiology NVM Reflections, Professor Nicolas Van Mieghem delivers a sharp, practice-focused wrap-up of TCT 2025 from San Francisco. From the SELUTION trials redefining the role of drug-coated balloons, with nearly 80% of patients avoiding a stent, to cost-conscious calcium modification strategies in SHORTCUT and VICTORY, he distills complex data into actionable insights you can use on your next case.
Professor Van Mieghem also dives into the STORM-PE trial, showing how catheter thrombectomy transforms outcomes in intermediate to high-risk pulmonary embolism. He reviews seven-year results from PARTNER 3 confirming long-term TAVR durability, and explores ENCIRCLE TMVR data that raise new questions about stroke and thrombosis management.
Rounding out the episode, he highlights long-term coronary data from NOBLE, PROCTOR, and iCABG, alongside emerging signals from INFINITY SWEDEHEART and ANDES.
Expect pragmatic thresholds, smart device selection tips, and an honest appraisal of what truly changes clinical practice after TCT 2025.
